病例PFS 超 21 个月，赛沃替尼助力合并脑转移原发 MET 扩增肺癌患者突破生存难关

导语：合并脑转移原发 MET 扩增肺癌患者，接受赛沃替尼实现持续获益。

内容策划：方程

项目审核：杨静

参考文献：

[1]Cheema PK, et al. Canadian Consensus Recommendations on the Management of MET-Altered NSCLC. Curr Oncol. 2021;28(6):4552-4576.

[2]Le X, et al. Clinical response to tepotinib according to circulating tumor (ct) DNA biomarkers in patients with advanced NSCLC with high-level MET amplification (METamp) detected by liquid biopsy (LBx). 2022 ASCO 9121.

[3]Sequist LV, et al. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. Lancet Oncol. 2020;21(3):373-386.

[4]Kris MG, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. JAMA. 2014;311(19):1998-2006.

[5]Spitaleri G, et al. MET in Non-Small-Cell Lung Cancer (NSCLC): Cross 'a Long and Winding Road' Looking for a Target. Cancers (Basel). 2023;15(19):4779.

[6]Lu S, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study[J]. Lancet Respir Med. 2021;9(10):1154-1164.

[7]Ruppert AM, Beau-Faller M, Neuville A, et al. EGFR-TKI and lung adenocarcinoma with CNS relapse: interest of molecular follow-up[J]. Eur Respir J. 2009 Feb;33(2):436-40.

[8]Gainor JF, Stevens SE, Willers H, et al. Intracranial Activity of Gefitinib and Capmatinib in a Patient with Previously Treated Non-Small Cell Lung Cancer Harboring a Concurrent EGFR Mutation and MET Amplification[J]. J Thorac Oncol. 2020 Jan;15(1):e8-e10.